Silvio Danese to Middle Aged
This is a "connection" page, showing publications Silvio Danese has written about Middle Aged.
Connection Strength
0.199
-
Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. Am J Gastroenterol. 2020 10; 115(10):1719-1721.
Score: 0.014
-
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 10; 157(4):1007-1018.e7.
Score: 0.013
-
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis. 2018 Nov 28; 12(12):1385-1391.
Score: 0.013
-
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018 Aug 29; 12(9):1021-1029.
Score: 0.012
-
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):601-606.
Score: 0.012
-
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut. 2019 01; 68(1):40-48.
Score: 0.012
-
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. Minerva Gastroenterol Dietol. 2017 Dec; 63(4):319-326.
Score: 0.012
-
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
Score: 0.012
-
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Dig Liver Dis. 2017 Aug; 49(8):872-877.
Score: 0.011
-
Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017 Mar; 11(3):203-214.
Score: 0.011
-
Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013 Oct; 38(7):741-51.
Score: 0.009
-
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005 Apr; 100(4):886-95.
Score: 0.005
-
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology. 2021 06; 160(7):2435-2450.e34.
Score: 0.004
-
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. Pharmacol Res. 2020 10; 160:105061.
Score: 0.004
-
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 07; 69(7):1213-1217.
Score: 0.004
-
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1361-1369.
Score: 0.003
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1215-1226.
Score: 0.003
-
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019 07 17; 25(8):1399-1407.
Score: 0.003
-
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. J Crohns Colitis. 2019 Mar 30; 13(4):417-423.
Score: 0.003
-
Obstetric outcomes in patients who have undergone excisional treatment for high-grade cervical squamous intra-epithelial neoplasia. Eur J Obstet Gynecol Reprod Biol. 2019 May; 236:210-213.
Score: 0.003
-
The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018 11; 48(9):941-950.
Score: 0.003
-
Simplified laparoscopic sacropexy avoiding deep vaginal dissection. Int J Gynaecol Obstet. 2018 Nov; 143(2):239-245.
Score: 0.003
-
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
Score: 0.003
-
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 12 23; 390(10114):2779-2789.
Score: 0.003
-
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929.
Score: 0.003
-
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. BioDrugs. 2017 Jun; 31(3):223-237.
Score: 0.003
-
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 07 08; 390(10090):135-144.
Score: 0.003
-
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 05 04; 376(18):1723-1736.
Score: 0.003
-
Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Dig Liver Dis. 2017 Aug; 49(8):864-871.
Score: 0.003
-
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017 Jul; 153(1):77-86.e6.
Score: 0.003
-
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018 01; 67(1):53-60.
Score: 0.003
-
Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. J Crohns Colitis. 2015 Jul; 9(7):541-7.
Score: 0.002